Type(s) of chemotherapy-Protocols (combined treatment)-DA-EPOCH Posts on Medivizor
Navigation Menu

Type(s) of chemotherapy-Protocols (combined treatment)-DA-EPOCH Posts on Medivizor

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Evaluating the effectiveness and safety of venetoclax with dose-adjusted EPOCH-R as initial therapy for patients with aggressive B-cell lymphoma.

Posted by on Sep 18, 2022 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of adding venetoclax (Venclexta) to a dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) regimen as initial therapy in patients with aggressive B-cell lymphoma. The data showed that venetoclax with dose-adjusted EPOCH-R was effective...

Read More

R-CHOP is associated with an increased risk of fractures in older patients with aggressive B-cell non-Hodgkin lymphoma.

R-CHOP is associated with an increased risk of fractures in older patients with aggressive B-cell non-Hodgkin lymphoma.

Posted by on May 16, 2021 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the occurrence of fractures and identified factors associated with a higher risk of fractures in patients with aggressive non-Hodgkin lymphoma (NHL) who received R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone)-like therapy. The data showed that there is a higher risk of...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2025 Medivizor